Search results for:
One woman’s complicated journey to a hemophilia C diagnosis
Ina Fowler, 68, of Brooksville, Florida, lives with several conditions, including hemophilia C, platelet dysfunction, atrial fibrillation, and peripheral artery disease. She recently suffered a brain bleed. To learn more about Ina’s journey, I spoke with her via Zoom. When Ina was in second grade, she hemorrhaged after a…
WHO updates hemophilia therapies on its essential medicines list
With encouragement from the World Federation of Hemophilia (WFH) and its partners, the World Health Organization (WHO) updated its essential medicines lists to better align with international clinical guidelines for managing hemophilia and other bleeding disorders. These lists — the Essential Medicines List (EML) and the…
Hemophilia lab test update ensures accuracy with new treatments
Precision Biologic has announced an update of its Cryocheck Chromogenic Factor VIII assay, a test used to help diagnose and manage hemophilia A. The update, which is expected to be commercially available in the coming months, will ensure that the assay’s accuracy is not compromised by a new…
Humate-P (human antihemophilic factor/von Willebrand factor complex) for hemophilia
Humate-P (human antihemophilic factor/von Willebrand factor complex) is a plasma-derived factor replacement therapy approved to prevent and treat bleeding episodes in people with hemophilia A.
Hemophilia care in the Philippines: Stories from the provinces
When I traveled with HAPLOS, the Hemophilia Philippines Foundation, about six years ago to visit families with bleeding disorders in rural provinces, I expected hardship. What I didn’t expect was how drastically the same diagnosis could play out depending on where and how you lived. My husband, Jared,…
Language matters in hemophilia, because we’re more than a label
When you live with a bleeding disorder, you quickly learn that the words people use matter almost as much as the treatments themselves. I’ve been called a “carrier” and a “hemophiliac,” and told that my condition was “mild” or “moderate,” as if these words fully described the challenges…
Hemlibra may help active men with hemophilia A stay in the game
For physically active men with severe hemophilia A, switching from their standard preventive treatment to Hemlibra (emicizumab-kxwh) can help reduce bleeding, a recent study suggests. This change not only improved their quality of life but also reduced the burden of treatment, allowing them to maintain their active lives.
Koāte (human antihemophilic factor) for hemophilia
Koāte (human antihemophilic factor) is a plasma-derived factor replacement therapy approved to prevent and control bleeding episodes or help manage bleeds during surgery in people with hemophilia A.